Amtagvi (lifileucel) — Medica
unresectable or metastatic melanoma
Initial criteria
- age ≥ 18 years
- unresectable or metastatic disease
- has been treated with a programmed death receptor-1 (PD-1) blocking antibody or a programmed death-ligand 1 (PD-L1) blocking antibody
- if BRAF V600 mutation positive, has been treated with a BRAF inhibitor with or without a MEK inhibitor
- has received or is planning to receive lymphodepleting chemotherapy prior to infusion of Amtagvi
- has NOT been previously treated with Amtagvi
- prescribed by or in consultation with an oncologist
Approval duration
6 months